Revenues Revenues (Tables)

3 Months Ended

Mar. 31, 2018

Revenues by product are summarized as follows:



	For the Three Months Ended March 31,
(In millions)	2018						2017
	United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis:
TECFIDERA	$	728.9	$	258.0	$	986.9	$	751.1	$	207.1	$	958.2
Interferon*	371.4		178.9		550.3		464.8		183.5		648.3
TYSABRI	249.7		212.4		462.1		305.5		239.5		545.0
FAMPYRA	—		24.4		24.4		—		20.5		20.5
ZINBRYTA	—		1.4		1.4		—		10.7		10.7
Spinal Muscular Atrophy:
SPINRAZA	188.0		175.9		363.9		46.4		1.0		47.4
Hemophilia:
ELOCTATE	—		—		—		42.2		6.2		48.4
ALPROLIX	—		—		—		21.0		5.0		26.0
Other Product Revenues:
FUMADERM	—		7.0		7.0		—		9.7		9.7
BENEPALI	—		120.9		120.9		—		65.3		65.3
FLIXABI	—		6.6		6.6		—		0.6		0.6
Total product revenues	$	1,538.0	$	985.5	$	2,523.5	$	1,631.0	$	749.1	$	2,380.1

*Interferon includes AVONEX and PLEGRIDY

An analysis of the change in reserves for discounts and allowances is summarized as follows:



(In millions)	Discounts			Contractual Adjustments			Returns			Total
Balance, as of December 31, 2017	$	109.6		$	606.0		$	46.0		$	761.6
Current provisions relating to sales in current year	159.4			641.2			5.8			806.4
Adjustments relating to prior years	1.2			2.0			0.3			3.5
Payments/credits relating to sales in current year	(71.7		)	(227.7		)	(0.3		)	(299.7		)
Payments/credits relating to sales in prior years	(77.4		)	(326.4		)	(8.7		)	(412.5		)
Balance, as of March 31, 2018	$	121.1		$	695.1		$	43.1		$	859.3

The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:



(In millions)	As of March 31, 2018		As of December 31, 2017
Reduction of accounts receivable	$	201.8	$	189.6
Component of accrued expenses and other	657.5		572.0
Total reserves	$	859.3	$	761.6

Revenues from anti-CD20 therapeutic programs are summarized as follows:



	For the Three Months Ended March 31,
(In millions)	2018		2017
Biogen’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA	$	349.6	$	323.5
Other revenues from anti-CD20 therapeutic programs	93.6		17.1
Total revenues from anti-CD20 therapeutic programs	$	443.2	$	340.6

Other revenues are summarized as follows:



	For the Three Months Ended March 31,
(In millions)	2018			2017
Revenues from collaborative and other relationships:
AbbVie	$	(4.7	)	$	(5.9	)
Samsung Bioepis and other	17.9			12.2
Other royalty and corporate revenues:
Royalty	10.6			25.5
Other corporate	140.6			58.2
Total other revenues	$	164.4		$	90.0